Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cells ; 11(16)2022 08 11.
Article in English | MEDLINE | ID: mdl-36010575

ABSTRACT

Long-term use of Glucocorticoids produces skeletal muscle atrophy and microvascular rarefaction. Hydrogen sulfide (H2S) has a potential role in skeletal muscle regeneration. However, the mechanisms still need to be elucidated. This is the first study to explore the effect of Sodium hydrosulfide (NaHS) H2S donor, against Dexamethasone (Dex)-induced soleus muscle atrophy and microvascular rarefaction and on muscle endothelial progenitors and M2 macrophages. Rats received either; saline, Dex (0.6 mg/Kg/day), Dex + NaHS (5 mg/Kg/day), or Dex + Aminooxyacetic acid (AOAA), a blocker of H2S (10 mg/Kg/day) for two weeks. The soleus muscle was examined for contractile properties. mRNA expression for Myostatin, Mechano-growth factor (MGF) and NADPH oxidase (NOX4), HE staining, and immunohistochemical staining for caspase-3, CD34 (Endothelial progenitor marker), vascular endothelial growth factor (VEGF), CD31 (endothelial marker), and CD163 (M2 macrophage marker) was performed. NaHS could improve the contractile properties and decrease oxidative stress, muscle atrophy, and the expression of NOX4, caspase-3, Myostatin, VEGF, and CD31 and could increase the capillary density and expression of MGF with a significant increase in expression of CD34 and CD163 as compared to Dex group. However, AOAA worsened the studied parameters. Therefore, H2S can be a promising target to attenuate muscle atrophy and microvascular rarefaction.


Subject(s)
Hydrogen Sulfide , Microvascular Rarefaction , Animals , Caspase 3 , Dexamethasone/adverse effects , Hydrogen Sulfide/metabolism , Hydrogen Sulfide/pharmacology , Macrophages/metabolism , Muscular Atrophy , Myostatin , NADPH Oxidase 4 , NADPH Oxidases , Rats , Vascular Endothelial Growth Factor A
2.
Immunol Res ; 68(5): 255-268, 2020 10.
Article in English | MEDLINE | ID: mdl-32734446

ABSTRACT

To compare human adipose tissue mesenchymal stem cells (AT-MSCs) and etanercept as immunomodulatory agents for collagen-induced arthritis (CIA). CIA was induced by rats' immunization with collagen type II (CII) in complete Freund's adjuvant in days 0 and 7. Before the onset of CIA, prevention group received five doses of AT-MSCS intraperitoneally. After establishment of arthritis, rats received either five doses of AT-MSCs or phosphate-buffered saline (PBS) intraperitoneally or six doses of etanercept subcutaneously. Clinical and histopathological evaluation were performed in all groups; serum levels of tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and anti-collagen II were assessed by enzyme-linked immunosorbent assay (ELISA). A total percent of autoreactive T and regulatory T (Treg) cells were quantified using spleen immune histochemical analysis. AT-MSCs were able to delay the onset of CIA, suppress the ongoing clinical and histopathological signs, decrease serum levels of TNF-α and anti-collagen type II, and downregulate the autoreactive T cells as etanercept. AT-MSCs were more potent in Treg cells upregulation, producing high serum levels of IL10. AT-MSCs might have a therapeutic effect in CIA via their potency in immune cell education, representing an effective new promising approach in rheumatoid arthritis in human.


Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Experimental/therapy , Arthritis, Rheumatoid/therapy , Etanercept/therapeutic use , Mesenchymal Stem Cell Transplantation , Adipose Tissue/cytology , Animals , Arthritis, Experimental/blood , Arthritis, Experimental/immunology , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/immunology , Collagen Type II/administration & dosage , Collagen Type II/immunology , Female , Freund's Adjuvant/administration & dosage , Freund's Adjuvant/immunology , Humans , Interleukin-10/blood , Interleukin-10/immunology , Rats , T-Lymphocytes, Regulatory/immunology , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/immunology
3.
Can J Physiol Pharmacol ; 92(9): 733-43, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25093892

ABSTRACT

OBJECTIVES: To study the effects of bone-marrow-derived mesenchymal stem cells (BM-MSCs) on adriamycin (ADR)-induced chronic nephropathy in rats. METHODS: 60 male Sprague-Dawley rats were distributed among 3 groups (20 rats each): (i) the negative control group, which was normal rats that received saline (vehicle); (ii) the positive control (ADR) group, which was rats that received 2 intravenous injections of ADR into the penile vein at 14 day intervals without treatment, and (iii) the MSC group, which were rats treated as for the ADR group that were also given 2 intravenous injections of MSCs (5 days after each ADR injection). RESULTS: ADR caused a significant reduction in animal body mass, survival rate, hemoglobin (Hb) content, serum albumin, and renal GSH, and significantly increased serum levels of triglycerides, cholesterol, urinary protein excretion and kidney injury molecule-1 (KIM-1), renal MDA, as well as caspase-3 expression and glomerular and tubulointerstitial damage compared with the negative control group. MSC treatment failed to improve animal survival rate, body mass, Hb level, proteinuria, or hypoalbuminemia; however, it mildly improved the serum BUN, hyperlipidemia, caspase-3 expression, urinary levels of KIM-1, renal oxidative stress markers, and glomerular and tubulointerstitial damage score. CONCLUSION: administration of BM-MSCs during induction of ADR nephropathy provides partial protection, which could be due to improvements in the levels of of endogenous antioxidants, reduction of apoptosis, and maintenance of the integrity of the glomerular membrane.


Subject(s)
Antibiotics, Antineoplastic/adverse effects , Bone Marrow Transplantation , Doxorubicin/adverse effects , Mesenchymal Stem Cell Transplantation , Renal Insufficiency, Chronic/therapy , Animals , Apoptosis Regulatory Proteins/metabolism , Biomarkers/metabolism , Body Weight/drug effects , Kidney/pathology , Male , Oxidative Stress/drug effects , Rats, Sprague-Dawley , Renal Insufficiency, Chronic/chemically induced , Renal Insufficiency, Chronic/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...